Advanced Biomedical Technologies (OTCMKTS:ABMT – Get Rating) and Bone Biologics (OTC:BBLG – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, dividends and valuation.
Profitability
This table compares Advanced Biomedical Technologies and Bone Biologics' net margins, return on equity and return on assets.
Get Advanced Biomedical Technologies alerts:| Net Margins | Return on Equity | Return on Assets | |
| Advanced Biomedical Technologies | N/A | N/A | N/A |
| Bone Biologics | N/A | -27.03% | -23.34% |
Risk & Volatility
Advanced Biomedical Technologies has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, Bone Biologics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.
Institutional & Insider Ownership
7.6% of Bone Biologics shares are held by institutional investors. 34.1% of Advanced Biomedical Technologies shares are held by insiders. Comparatively, 71.5% of Bone Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Advanced Biomedical Technologies and Bone Biologics' top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Advanced Biomedical Technologies | $120,000.00 | 26.59 | -$670,000.00 | N/A | N/A |
| Bone Biologics | N/A | N/A | -$1.49 million | N/A | N/A |
Advanced Biomedical Technologies has higher revenue and earnings than Bone Biologics.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Advanced Biomedical Technologies and Bone Biologics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Advanced Biomedical Technologies | 0 | 0 | 0 | 0 | N/A |
| Bone Biologics | 0 | 0 | 1 | 0 | 3.00 |
Bone Biologics has a consensus price target of $2.25, suggesting a potential upside of 765.38%. Given Bone Biologics' higher possible upside, analysts clearly believe Bone Biologics is more favorable than Advanced Biomedical Technologies.
Summary
Bone Biologics beats Advanced Biomedical Technologies on 5 of the 9 factors compared between the two stocks.
About Advanced Biomedical Technologies
(Get Rating)
Advanced BioMedical Technologies, Inc. engages in the provision of medical and pain management tools. Its products include Electro-Acuscope 85P (Portable), Electro-Acuscope 80L, Neuroscope 230B, Electro-Myopulse 75L (Base Model), Electro-Myopulse 75F (Used in Fermi Lab Study), and Electro-Myopulse EMS 85P (Portable). The company was founded in 1984 and is headquartered in New York, NY.
About Bone Biologics
(Get Rating)
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
Receive News & Ratings for Advanced Biomedical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Biomedical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.